Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 2 | 2022 | 196 | 1.440 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2022 | 52 | 1.060 |
Why?
|
End Stage Liver Disease | 1 | 2021 | 18 | 0.850 |
Why?
|
Hydronephrosis | 1 | 2020 | 7 | 0.800 |
Why?
|
Ureteral Obstruction | 1 | 2020 | 9 | 0.800 |
Why?
|
Kidney Pelvis | 1 | 2020 | 6 | 0.790 |
Why?
|
Ureter | 1 | 2020 | 20 | 0.780 |
Why?
|
Cysts | 1 | 2020 | 36 | 0.780 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 210 | 0.720 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 277 | 0.660 |
Why?
|
Postoperative Complications | 1 | 2021 | 881 | 0.560 |
Why?
|
Gout Suppressants | 1 | 2015 | 28 | 0.550 |
Why?
|
Gout | 1 | 2015 | 52 | 0.530 |
Why?
|
Medication Adherence | 1 | 2015 | 249 | 0.460 |
Why?
|
Neoplasms | 1 | 2022 | 1058 | 0.460 |
Why?
|
Transplant Recipients | 2 | 2022 | 18 | 0.440 |
Why?
|
Cholangitis, Sclerosing | 2 | 2021 | 6 | 0.390 |
Why?
|
Incidence | 2 | 2022 | 1122 | 0.350 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 142 | 0.340 |
Why?
|
Liver Neoplasms | 2 | 2021 | 237 | 0.310 |
Why?
|
Presenilin-1 | 2 | 2012 | 49 | 0.230 |
Why?
|
Risk Factors | 2 | 2022 | 4248 | 0.230 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 20 | 0.220 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 10 | 0.220 |
Why?
|
SEER Program | 1 | 2021 | 69 | 0.210 |
Why?
|
Retroperitoneal Space | 1 | 2020 | 16 | 0.200 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2019 | 4 | 0.190 |
Why?
|
Nephrectomy | 1 | 2020 | 54 | 0.190 |
Why?
|
bcl-X Protein | 1 | 2019 | 13 | 0.190 |
Why?
|
Drainage | 1 | 2020 | 104 | 0.190 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 198 | 0.180 |
Why?
|
Male | 5 | 2022 | 23140 | 0.180 |
Why?
|
Alzheimer Disease | 2 | 2012 | 395 | 0.170 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2017 | 10 | 0.160 |
Why?
|
Humans | 9 | 2022 | 49675 | 0.160 |
Why?
|
Age Factors | 1 | 2021 | 1410 | 0.160 |
Why?
|
Population Surveillance | 1 | 2018 | 204 | 0.160 |
Why?
|
Adult | 3 | 2021 | 13334 | 0.150 |
Why?
|
Risk Assessment | 1 | 2021 | 1574 | 0.140 |
Why?
|
Amyloid beta-Peptides | 2 | 2012 | 148 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 1049 | 0.130 |
Why?
|
Apoptosis | 1 | 2019 | 978 | 0.130 |
Why?
|
Retrospective Studies | 2 | 2021 | 4517 | 0.120 |
Why?
|
Disease Management | 1 | 2015 | 178 | 0.120 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2012 | 65 | 0.110 |
Why?
|
Chronic Disease | 1 | 2015 | 671 | 0.110 |
Why?
|
Transcription Factors | 1 | 2019 | 1356 | 0.110 |
Why?
|
Quality Improvement | 1 | 2015 | 321 | 0.100 |
Why?
|
Neurons | 2 | 2012 | 757 | 0.100 |
Why?
|
Middle Aged | 3 | 2021 | 13451 | 0.100 |
Why?
|
Aging | 1 | 2012 | 680 | 0.080 |
Why?
|
Female | 4 | 2021 | 26343 | 0.080 |
Why?
|
Aged | 1 | 2021 | 10870 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2012 | 811 | 0.050 |
Why?
|
Mice, Transgenic | 2 | 2012 | 1114 | 0.050 |
Why?
|
Cellular Senescence | 1 | 2019 | 90 | 0.050 |
Why?
|
Hepatocytes | 1 | 2019 | 169 | 0.040 |
Why?
|
Mice | 3 | 2019 | 9096 | 0.040 |
Why?
|
Blood Viscosity | 1 | 2017 | 3 | 0.040 |
Why?
|
Plasmapheresis | 1 | 2017 | 12 | 0.040 |
Why?
|
Muscle Weakness | 1 | 2017 | 23 | 0.040 |
Why?
|
Rituximab | 1 | 2017 | 66 | 0.040 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2017 | 40 | 0.040 |
Why?
|
Survival Analysis | 1 | 2018 | 473 | 0.040 |
Why?
|
Lipopolysaccharides | 1 | 2019 | 623 | 0.040 |
Why?
|
Accidental Falls | 1 | 2017 | 130 | 0.040 |
Why?
|
Liver | 1 | 2019 | 709 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2017 | 750 | 0.030 |
Why?
|
Animals | 3 | 2019 | 17732 | 0.030 |
Why?
|
Frontotemporal Lobar Degeneration | 1 | 2012 | 9 | 0.030 |
Why?
|
Plaque, Amyloid | 1 | 2012 | 27 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2012 | 113 | 0.030 |
Why?
|
Feedback, Physiological | 1 | 2012 | 55 | 0.030 |
Why?
|
Blotting, Western | 1 | 2012 | 534 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2012 | 325 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 371 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2012 | 249 | 0.030 |
Why?
|
Protein Conformation | 1 | 2012 | 718 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2012 | 2017 | 0.020 |
Why?
|
United States | 1 | 2018 | 6234 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2012 | 4220 | 0.020 |
Why?
|